Popular searches
Product scoring may vary based on gender, age, policy tenure and sum assured.
The lowest age in the selected range is considered for price evaluation (e.g., 25 - 29)

Active Funds • Sector Funds • NIFTY PHARMA - TRI
15
15
This fund ranks 15th out of 82 funds in its category.
| Avg. Rolling Returns | 1 year | 3 year | 5 year | 7 year |
|---|
| Avg. Rolling Returns |
|---|
| 1 Years |
| 3 Years |
| 5 Years |
| 7 Years |
“80% of mutual fund schemes lose 25% or more value due to commissions in 10 years.” Source: 1 Finance Research
Score Trend
*Most top-ranked mutual funds won't hold their rank for long. Source: 1 Finance Research
| Holding Names | Assets (%) |
|---|---|
| Sun Pharmaceutical Industries Ltd. | 12.05% |
| Cipla Ltd. | 7.90% |
| Dr. Reddy's Laboratories Ltd. | 7.82% |
| Divi's Laboratories Ltd. | 7.10% |
| Mankind Pharma Ltd. | 6.44% |
*Most active equity funds don't beat their own benchmark over the long run. Source: 1 Finance Research
| Fund List | 1 F score | Fund Size | Expense Ratio |
|---|
*Most financial mistakes aren't about money — they're about personality. Find yours with MoneySign®
Lumpsum
₹ 5000 (open for subscription)
| Fund Manager Name | Total Exp. (Years) | No. of Funds Managed |
|---|---|---|
| Dharmesh Kakkad | 6.6 | 2 |



Our Advisory Includes
Through a secure infrastructure, RSA-256 encryption, disaster recovery protocols





The Information in the scoring and ranking model is provided solely for general information and educational purposes and shall not constitute any advice or recommendation. Mutual Fund investments are subject to market risks. Please read all scheme-related documents carefully before investing. Past performance is not an indicator of future returns.